Diacerein
- Generic Name
- Diacerein
- Drug Type
- Small Molecule
- Chemical Formula
- C19H12O8
- CAS Number
- 13739-02-1
- Unique Ingredient Identifier
- 4HU6J11EL5
- Background
Diacerein is a prodrug which is metabolized to rhein. It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea . Diacerein is under investigation for the treatment of Insulin Resistance, Diabetes Mellitus (Type 2), and Diabetes-Related Complications.
- Indication
For the treatment of osteoarthritis affecting the hip or knee .
- Associated Conditions
- Osteoarthritis in the Hip Joint, Osteoarthritis of the Knee
Efficacy of Diacerein Supplementation on Interleukin-1β, Hs-CRP, TNF-α Levels and Glycemic Control in Uncontrolled Type 2 Diabetes Mellitus Patients at Dr. Mohammad Hoesin General Hospital Palembang
- Conditions
- Uncontrolled DiabetesDiabetes Mellitus Type 2
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Universitas Sriwijaya
- Target Recruit Count
- 34
- Registration Number
- NCT06912035
- Locations
- 🇮🇩
Universitas Sriwijaya, Palembang, South Sumatera, Indonesia
Bioequivalence Study of Diacerein 50 mg Capsule in Healthy Thai Volunteers
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- International Bio service
- Target Recruit Count
- 30
- Registration Number
- NCT06308068
Study Design of the Diacerein in Patients With Covid-19
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- University of Campinas, Brazil
- Target Recruit Count
- 40
- Registration Number
- NCT05226754
- Locations
- 🇧🇷
Unicamp Clinical Hospital, Campinas, São Paulo, Brazil
🇧🇷Hospital Estadual Sumaré, Sumaré, São Paulo, Brazil
Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Chulalongkorn University
- Target Recruit Count
- 34
- Registration Number
- NCT04351100
- Locations
- 🇹🇭
Faculty of medicine, Chulalongkorn university, Bangkok, Thailand
A 6-Week Study to Evaluate the Photoallergic Potential of Diacerein 1% Ointment in Healthy Volunteers
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Castle Creek Pharmaceuticals, LLC
- Target Recruit Count
- 61
- Registration Number
- NCT03473197
- Locations
- 🇺🇸
TKL Research, Fair Lawn, New Jersey, United States
A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Castle Creek Pharmaceuticals, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT03473184
- Locations
- 🇺🇸
TKL Research, Fair Lawn, New Jersey, United States
A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- Castle Creek Pharmaceuticals, LLC
- Target Recruit Count
- 234
- Registration Number
- NCT03472547
- Locations
- 🇺🇸
TKL Research, Fair Lawn, New Jersey, United States
To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)
- Conditions
- Epidermolysis Bullosa (EB)Epidermolysis Bullosa SimplexDystrophic Epidermolysis BullosaJunctional Epidermolysis Bullosa
- Interventions
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Castle Creek Pharmaceuticals, LLC
- Target Recruit Count
- 11
- Registration Number
- NCT03472287
- Locations
- 🇺🇸
Stanford School of Medicine, Palo Alto, California, United States
🇺🇸UNC Dermatology, Chapel Hill, North Carolina, United States
🇺🇸Northwestern University Medical Center, Chicago, Illinois, United States
A 21 Day Irritation Study in Healthy Volunteers With Diacerein 1% Ointment
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Castle Creek Pharmaceuticals, LLC
- Target Recruit Count
- 46
- Registration Number
- NCT03472534
- Locations
- 🇺🇸
TKL Research, Fair Lawn, New Jersey, United States
Trial to Evaluate Efficacy and Safety of Combination of Diacerein and Celecoxib Administered in Patients With Knee OA
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- Whan-Seok Choi
- Target Recruit Count
- 90
- Registration Number
- NCT03404479
- Locations
- 🇰🇷
Seoul ST. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Korea University Guro Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.